Stemline Therapeutics (STML) Receiving Somewhat Favorable Press Coverage, Accern Reports

Headlines about Stemline Therapeutics (NASDAQ:STML) have trended somewhat positive this week, Accern reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Stemline Therapeutics earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.8745387936377 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Stemline Therapeutics (STML) opened at $14.10 on Monday. Stemline Therapeutics has a 1-year low of $5.50 and a 1-year high of $16.20. The company has a market cap of $356.55, a PE ratio of -5.49 and a beta of -0.02.

Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.68) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.11). Stemline Therapeutics had a negative net margin of 4,689.63% and a negative return on equity of 75.50%. equities analysts predict that Stemline Therapeutics will post -2.71 earnings per share for the current year.

A number of equities research analysts have weighed in on STML shares. BidaskClub upgraded shares of Stemline Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, January 4th. HC Wainwright restated a “buy” rating and issued a $38.00 price objective on shares of Stemline Therapeutics in a research note on Friday, November 10th. Cowen restated a “buy” rating on shares of Stemline Therapeutics in a research note on Tuesday, October 31st. Zacks Investment Research upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, January 5th. Finally, ValuEngine upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $33.75.

In other Stemline Therapeutics news, COO Kenneth Hoberman sold 11,943 shares of the firm’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $14.18, for a total value of $169,351.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders sold 37,966 shares of company stock valued at $534,848. 15.70% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: “Stemline Therapeutics (STML) Receiving Somewhat Favorable Press Coverage, Accern Reports” was originally published by BBNS and is owned by of BBNS. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://baseballnewssource.com/markets/stemline-therapeutics-stml-earns-news-sentiment-score-of-0-08/1813196.html.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Insider Buying and Selling by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with our FREE daily email newsletter.

 


Latest News

Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
Trade Rumor: Manny Machado Could Land With Yankees
Trade Rumor: Manny Machado Could Land With Yankees
Los Angeles Dodgers Acquire Scott Alexander as Part of Three Team Deal
Los Angeles Dodgers Acquire Scott Alexander as Part of Three Team Deal


Leave a Reply

 
© 2006-2018 BBNS.